Delcath Systems (DCTH) Projected to Post Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Delcath Systems to post earnings of ($0.0971) per share and revenue of $23.5090 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Delcath Systems (NASDAQ:DCTH) last announced its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $20.73 million during the quarter, compared to analyst estimates of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.63%. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Delcath Systems Stock Performance

NASDAQ DCTH traded down $0.04 on Wednesday, reaching $11.49. The company had a trading volume of 119,972 shares, compared to its average volume of 416,321. The firm has a market capitalization of $395.95 million, a price-to-earnings ratio of 164.14 and a beta of 0.54. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $18.23. The company’s fifty day moving average is $9.81 and its 200-day moving average is $9.83.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd lifted its position in Delcath Systems by 339.4% during the 4th quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock worth $719,000 after buying an additional 54,990 shares in the last quarter. Millennium Management LLC lifted its position in Delcath Systems by 3.0% during the 4th quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock worth $2,489,000 after buying an additional 7,190 shares in the last quarter. Man Group plc lifted its position in Delcath Systems by 34.1% during the 4th quarter. Man Group plc now owns 38,158 shares of the company’s stock worth $385,000 after buying an additional 9,705 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in Delcath Systems by 69.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock worth $527,000 after buying an additional 21,384 shares in the last quarter. Finally, Jump Financial LLC lifted its position in Delcath Systems by 68.0% during the 4th quarter. Jump Financial LLC now owns 45,953 shares of the company’s stock worth $464,000 after buying an additional 18,596 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on DCTH. BTIG Research reduced their target price on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Evercore set a $27.00 target price on shares of Delcath Systems in a research note on Thursday, February 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Delcath Systems in a research note on Friday, January 9th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.